Date: 2014-04-02
Type of information: R&D agreement
Compound:
Company: Evotec (Germany) Debiopharm (Switzerland)
Therapeutic area: Cancer - Oncology
Type agreement: R&D
licensing
Action mechanism:
Disease: solid tumors and leukemias with defined genetic alterations
Details: * On April 2, 2014, Evotec has announced a research collaboration and licensing deal with Debiopharm Group™. The objective of this collaboration is to identify and develop novel compounds having the potential to treat multiple forms of solid tumors and leukemias with defined genetic alterations. Discovery and pre-clinical development efforts will be driven by Evotec, whilst Debiopharm will manage clinical development. Evotec will receive R&D funding and high double-digit total payments triggered by clinical, regulatory and commercial milestones, plus royalties on sales of resulting commercial products.
This program is based on Evotec\'s drug discovery efforts to investigate genetically altered targets whose \'driver\' role in several cancer types has been validated and on the shared objective of identifying novel therapeutic agents in a variety of cancers, including AML (Acute Myeloid Leukemia), prostate cancer and glioblastoma. \"Through this collaboration with Evotec, Debiopharm is strengthening its position in early projects with a leader in the drug discovery field\" said Thierry Mauvernay, Delegate of the Board of Debiopharm Group \". Furthermore, this R&D program targeting cancers with known genetic alterations is a whole part of our strategy for personalized medicines\".
Financial terms:
Latest news:
